Skip to main content
ANTEROGEN CO., LTD. logo

ANTEROGEN CO., LTD. — Investor Relations & Filings

Ticker · 065660 ISIN · KR7065660003 KO Manufacturing
Open in API
Filings indexed 267 across all filing types
Latest filing 2020-04-24 Capital/Financing Update
Country KR South Korea
Listing KO 065660

About ANTEROGEN CO., LTD.

http://anterogen.com

ANTEROGEN CO., LTD. is a bio-venture company engaged in the research, development, and commercialization of cell therapy products and orphan drugs. The company specializes in utilizing adult stem cells, particularly adipose-derived mesenchymal stem cells, to create innovative treatments. Its key commercialized products include Cupistem®, an autologous stem cell therapy for Crohn's fistula, and Queencell®. Anterogen's research pipeline extends to applications for musculoskeletal diseases, spinal injuries, and cardiovascular conditions. The company also offers stem cell banking services.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시)(제4회차 CB)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Antrogen) titled '증권 발행결과' (Securities Issuance Result) regarding the issuance of convertible bonds (CB). This falls under the category of capital and financing updates as it details the completion of a debt-to-equity financing instrument.
2020-04-24 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange regarding the issuance of convertible bonds (전환사채권 발행결정). It details the terms of the issuance, including interest rates, conversion rights, call/put options, and the list of investors. This falls under the category of capital and financing updates as it describes the company's fundraising activity through debt instruments.
2020-04-23 Korean
사업보고서 (2019.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Antrogen Co., Ltd. for the fiscal year ending December 31, 2019. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes to the financial statements. While it contains financial data, it is a formal audit report rather than a full 10-K annual report or a simple earnings release. In the context of the provided categories, 'AR' (Audit Report) is the most accurate classification. FY 2019
2020-03-27 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (DART system) used when a shareholder's stake in a company crosses a specific threshold (typically 5%). This document details the change in shareholding by Bukwang Pharm in Antrogen due to market sales. This falls under the 'Major Shareholding Notification' category.
2020-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of an Annual General Meeting (AGM) for the company 'Antrogen'. It details the approval of financial statements, dividend resolutions, election of directors, and other agenda items voted upon during the meeting held on 2020-03-23. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-03-23 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or resignation of an outside director (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This falls under the category of changes in the company's board of directors or senior management.
2020-03-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.